The ColoFuture study, a multi-center international clinical trial assessing the potential to integrate a portfolio of novel mRNA biomarkers into ColoAlert, has demonstrated positive topline results.
A study by University of Arizona Cancer Center researchers piloted a unique outreach strategy to foster dialogue between basic scientists and community members to demystify basic science research and facilitate culturally tailored approaches to address health disparities of vulnerable communities.
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer, the biomarker-driven Lung Cancer Master Protocol, or Lung-MAP, has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.
OneOncology finalized 25 unique oncology and hematology pathways and published each pathway inside the platform’s clinical decision support tool.
Six-year results from part 1 of the phase III CheckMate -227 trial demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression levels.
Intensity-modulated radiation therapy should be the preferred choice when treating patients with locally advanced non-small cell lung cancer, as it reduces radiation exposure to the heart and lungs, according to researchers at MD Anderson Cancer Center.
Follow-up results from the phase Ib/II CHRYSALIS-2 study cohort evaluating the safety and tolerability of the combination of Rybrevant (amivantamab-vmjw)—a bispecific antibody targeting epidermal growth factor receptor and mesenchymal-epithelial transition—with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor, plus platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer and EGFR mutations, showed that the drug combination led to durable progression-free survival.
Long-term exposure to low-dose radiation is linked to an increased risk of cancer, according to a study led by the University of California, Irvine. In the U.S., radiation exposure for the average person doubled between 1985 and 2006, mainly from medical imaging procedures such as CT scans, highlighting the need for its judicious use.
Patient-reported outcomes data from the phase III NATALEE trial, presented at the European Society for Medical Oncology Virtual Plenary, show that a broad population of patients with stage 2 and 3 hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer maintained health-related quality of life during treatment with Kisqali (ribociclib) plus endocrine therapy.
A multicenter phase II clinical study conducted by the SWOG Cancer Research Network suggests that combination ipilimumab and nivolumab can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to PD-1 inhibitors.
